|
Daehan New Pharm Launches Fastin Tablet for Obesity Treatment
2005.01.07
|
|---|
|
Daehan New Pharm Strengthens Specialization in Obesity Treatment Field
Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) kicked off 2005 with the launch of new products including Fastin Tablet for obesity treatment and iCool Capsules for eye nutrition. At the New Year ceremony held at the Suwon Lavidol Resort with all employees in attendance, the company committed to achieving its sales goals for the year and making 2005 a year of corporate growth.
Fastin Tablet contain phentermine hydrochloride, a drug approved by the US FDA for appetite suppression in patients with exogenous obesity. Daehan New Pharm has actively marketed a diverse portfolio of products in the fields of appetite suppressants, fat absorption inhibitors, thermogenesis promoters, and obesity treatment mesotherapy formulations. The launch of Fastin Tablet, expected to capture a significant market, is aimed at cementing the company’s position as a specialist pharmaceutical company in obesity treatment.
The obesity treatment market was valued at approximately 50 billion KRW in 2004, and Daehan New Pharm anticipates capturing at least 15% of this market. Recognizing that many clinics show great interest in treating obesity patients but lack familiarity with patient engagement methods, the company plans to train obesity specialist coordinators and develop customer-centric marketing strategies. |


Home